☆ 4.6 Editorial Material

Definition and management of radioactive iodine-refractory differentiated thyroid cancer

LANCET DIABETES & ENDOCRINOLOGY (2014)

期刊

LANCET DIABETES & ENDOCRINOLOGY

卷 2, 期 5, 页码 356-358

出版社

ELSEVIER SCIENCE INC

DOI: 10.1016/S2213-8587(13)70215-8

关键词

-

类别

Endocrinology & Metabolism

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Article Pharmacology & Pharmacy

Cost-Effectiveness of Apatinib and Cabozantinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer

Bo Shi, Wenbiao Ma, Hongshuai Pan, Yang Shi, Huan Zhang, Shenghai Xing

Summary: This study evaluated the cost-effectiveness of apatinib and cabozantinib for RAIR-DTC from the perspective of the Chinese healthcare system. The results showed that apatinib is cost-effective compared to placebo, while cabozantinib may not be cost-effective and a reduction in price is warranted.

FRONTIERS IN PHARMACOLOGY (2022)

添加到收藏夹

Review Oncology

Advances in Functional Imaging of Differentiated Thyroid Cancer

Michele Klain, Emilia Zampella, Carmela Nappi, Emanuele Nicolai, Raffaele Ambrosio, Elena Califaretti, Livia Lamartina, Martin Schlumberger, Desiree Deandreis, Domenico Salvatore, Alberto Cuocolo

Summary: This review summarizes recent advances in functional imaging and theragnosis of DTC, focusing on the use of radioactive iodine for treatment and FDG uptake for diagnosis. It also discusses other potential tracers and technologies that may offer new opportunities in selecting specific imaging modalities or treatments for patients with DTC.

CANCERS (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Multikinase Inhibitors for the Treatment of Asymptomatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Global Noninterventional Study (RIFTOS MKI)

Marcia S. S. Brose, Johannes W. A. Smit, Chia-Chi Lin, Masayuki Tori, Daniel W. W. Bowles, Francis Worden, Daniel Hueng-Yuan Shen, Shih-Ming Huang, Hui-Jen Tsai, Maria Alevizaki, Robin P. P. Peeters, Shunji Takahashi, Pavel Rumyantsev, Rongjin Guan, Svetlana Babajanyan, Kirhan Ozgurdal, Iwao Sugitani, Fabian Pitoia, Livia Lamartina

Summary: Sorafenib and lenvatinib are approved for RAI-R DTC, but there is no consensus on when to initiate MKI treatment. This study evaluated TTSP in patients with RAI-R DTC for whom the decision to treat with an MKI was made at study entry. The results showed that most patients had a TTSP of 36 months or more, indicating a positive impact of MKIs on patient prognosis.

THYROID (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Dosimetry during adjuvant 131I therapy in patients with differentiated thyroid cancer-clinical implications

Piotr Szumowski, Saeid Abdelrazek, Dorota Iwanicka, Malgorzata Mojsak, Monika Sykala, Lukasz Zukowski, Katarzyna Siewko, Agnieszka Adamska, Katarzyna Maliszewska, Anna Poplawska-Kita, Malgorzata Szelachowska, Adam Kretowski, Janusz Mysliwiec

Summary: Dosimetry based on Marinelli's formula is essential for determining the radioiodine activity in adjuvant therapy for thyroid cancer. The retrospective analysis showed that adjusting therapeutic activities of I-131 based on dosimetry measurements can lead to successful outcomes for patients.

SCIENTIFIC REPORTS (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Low-Iodine Diet of 4 Days Is Sufficient Preparation for 131I Therapy in Differentiated Thyroid Cancer Patients

Bernadette L. Dekker, Mirthe H. Links, Anneke C. Muller Kobold, Linda G. Swart-Busscher, Marleen Kars, Judith A. P. Bons, Adrienne H. Brouwers, Thera P. Links, Anouk N. A. Van der Horst-Schrivers

Summary: This study investigated whether a 4-day low-iodine diet (LID) is sufficient for adequate iodine depletion in differentiated thyroid cancer (DTC) patients preparing for I-131 therapy. The results showed no significant difference in the 24-hour urinary iodine excretion (UIE) between day 4 and day 7 of the LID. On day 4, 72.1% of DTC patients achieved adequate preparation, increasing to 82.0% on day 7. Compared to their regular diet, DTC patients had significantly lower nutrient intake during the LID.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2022)

添加到收藏夹

Article Oncology

Risk and outcome of subsequent malignancies after radioactive iodine treatment in differentiated thyroid cancer patients

Xiaoran Mei, Xiaoqin Yao, Fang Feng, Weiwei Cheng, Hui Wang

Summary: This study found that DTC survivors had a slightly increased risk of developing other malignancies after receiving RAI treatment, but the attributable risk proportion associated with RAI was relatively low, indicating a low absolute number of malignancies induced by RAI in DTC survivors. The highest attributable risk proportion of RAI treatment was observed in hematological malignancies, but due to their low incidence among all DTC survivors, the absolute number of hematological malignancies was low.

BMC CANCER (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Non-Iodine-Avid Disease Is Highly Prevalent in Distant Metastatic Differentiated Thyroid Cancer With Papillary Histology

Myat Han Soe, Janet M. Chiang, Robert R. Flavell, Elham Khanafshar, Laura Mendoza, Hyunseok Kang, Chienying Liu

Summary: Patients with radioactive iodine refractory metastatic differentiated thyroid cancer have a poor prognosis. This study aimed to characterize patients with non-iodine-avid disease at diagnosis. The results showed that non-iodine-avid disease is highly prevalent in DTC patients with BVL cancers, particularly with BRAF (V600E) and TERT promoter mutations, and is associated with older age.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2022)

添加到收藏夹

Review Endocrinology & Metabolism

Current Controversies in Low-Risk Differentiated Thyroid Cancer: Reducing Overtreatment in an Era of Overdiagnosis

Timothy M. Ullmann, Maria Papaleontiou, Julie Ann Sosa

Summary: This review discusses the controversies and difficult decisions in the management of low-risk differentiated thyroid cancer (DTC) and provides recommendations. While overdiagnosis is a concern, the true incidence of DTC has also increased. Treatment options vary, and personalized and nuanced treatment decisions are necessary for clinicians and patients.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2023)

添加到收藏夹

Article Endocrinology & Metabolism

Disparities in Treatment for Differentiated Thyroid Cancer

Stephanie Davis, Timothy M. Ullmann, Sanziana Roman

Summary: This review examines the disparities in diagnosis and treatment of patients with differentiated thyroid cancer (DTC) and proposes practical clinical and policy ideas for improving the gap in treatment.

THYROID (2023)

添加到收藏夹

Review Oncology

Advances in the molecular mechanism and targeted therapy of radioactive-iodine refractory differentiated thyroid cancer

Lu Zhang, Zhi Li, Meng Zhang, Huangren Zou, Yuke Bai, Yanlin Liu, Juan Lv, Ling Lv, Pengjie Liu, Zhiyong Deng, Chao Liu

Summary: Most patients with differentiated thyroid cancer respond well to radioactive iodine-131 treatment, but a small number of patients show resistance and disease progression. Targeted drugs such as sorafenib and lenvatinib have shown promise in the treatment of this refractory cancer. However, their use is limited due to adverse reactions and drug resistance. Alternative treatments such as gene therapy and rutin-assisted iodine-131 therapy are being explored.

MEDICAL ONCOLOGY (2023)

添加到收藏夹

Article Endocrinology & Metabolism

Vascular Endothelial Growth Factor Receptor Inhibitors in Chinese Patients With Advanced Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Network Meta-Analysis and Cost-Effectiveness Analysis

Youwen Zhu, Kun Liu, Kailing Wang, Libo Peng

Summary: The study revealed that apatinib was more cost-effective compared to lenvatinib in the first-line treatment of Chinese patients with RAIR-DTC, as indicated by network meta-analysis and cost-effectiveness analysis results.

FRONTIERS IN ENDOCRINOLOGY (2022)

添加到收藏夹

Article Endocrinology & Metabolism

Redifferentiating Effect of Larotrectinib in NTRK-Rearranged Advanced Radioactive-Iodine Refractory Thyroid Cancer

Lionel Groussin, Helene Theodon, Laura Bessiene, Leopoldine Bricaire, Fideline Bonnet-Serrano, Beatrix Cochand-Priollet, Karen Leroy, Simon Garinet, Eric Pasmant, Jeremie Zerbit, Romain Seban, Francois Goldwasser, Jerome Clerc, Anne Segolene Cottereau, Olivier Huillard

Summary: Inhibitors may treat RAI-resistant cancers by activating RAI and providing antitumoral effects, but not all patients experience redifferentiation.

THYROID (2022)

添加到收藏夹

Article Endocrinology & Metabolism

Radioactive Iodine-Refractory Pulmonary Metastases of Papillary Thyroid Cancer in Children, Adolescents, and Young Adults

Tian Tian, Shuhui Huang, Hongyuan Dai, Mengfang Qi, Bin Liu, Rui Huang

Summary: This study investigated the clinicopathologic characteristics and prognosis of radioactive iodine-refractory (RAIR) papillary thyroid cancer in children, adolescents, and young adults. It found that younger patients are more susceptible to developing RAIR disease, which leads to unfavorable progression-free survival and disease-specific survival. RAIR disease was also identified as an independent predictor of progressive disease.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2023)

添加到收藏夹

Article Multidisciplinary Sciences

Prognostic value of adjuvant external beam radiotherapy for papillary thyroid cancer based on competitive risk model and propensity score matching

Jiani Zhou, Chaoqun Wu, Shihong Fan, Miaohui Zhao

Summary: This study assessed the impact of adjuvant external beam radiotherapy on the survival of patients with locally invasive papillary thyroid carcinoma. Data from the Surveillance, Epidemiology, and End Results database were used, and Cox models and propensity score matching were employed for analysis. The study found that adjuvant external beam radiotherapy did not provide a survival benefit in the initial management of locally invasive papillary thyroid cancer.

SCIENTIFIC REPORTS (2023)

添加到收藏夹

Article Endocrinology & Metabolism

Parathyroid Changes After RAI in Patients With Differentiated Thyroid Carcinoma

Liu Xiao, Wenjie Zhang, Hongmei Zhu, Yueqi Wang, Bin Liu, Rui Huang, Lin Li

Summary: This study investigated the changes in PTH, serum calcium, phosphorus, and 25-OH-VD levels before and after RAI in DTC patients, finding that about one-fifth of patients may experience hypocalcemia at five days post-RAI. Lower baseline pre-RAI serum calcium and PTH levels, as well as negative (TcO4)-Tc-99m (-) thyroid imaging, were identified as risk factors for hypocalcemia at five days post-RAI.

FRONTIERS IN ENDOCRINOLOGY (2021)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Patient-specific biokinetics and hybrid 2D/3D approach integration in OEDIPE software: Application to radioiodine therapy

M. Bensiali, N. Anizan, S. Leboulleux, S. Lamart, E. Davesne, D. Broggio, A. Desbree, D. France

Summary: The OEDIPE software was developed with new functionalities to handle multiple 3D or planar images and a SPECT image for patient-specific dosimetry. Methods were implemented to recover patient biokinetics and validate the software using phantom images and whole-body retention data. Results showed good agreement between the estimated activities and cumulated activities from the software and reference values.

PHYSICA MEDICA-EUROPEAN JOURNAL OF MEDICAL PHYSICS (2023)

添加到收藏夹

Article Oncology

Health-related quality-of-life analyses from a multicenter, randomized, double-blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24 mg/day

Matthew H. Taylor, Sophie Leboulleux, Yury Panaseykin, Bhavana Konda, Christelle de la Fouchardiere, Brett G. M. Hughes, Andrew G. Gianoukakis, Young Joo Park, Ilia Romanov, Monika K. Krzyzanowska, Diana Garbinsky, Bintu Sherif, Jie Janice Pan, Terri A. Binder, Nicholas Sauter, Ran Xie, Marcia S. Brose

Summary: In this study comparing the starting dose of lenvatinib 18 mg/day with 24 mg/day in RR-DTC patients, no significant difference was found in the health-related quality of life (HRQoL). These findings support the use of the approved lenvatinib starting dose of 24 mg/day in RR-DTC patients.

CANCER MEDICINE (2023)

添加到收藏夹

Article Endocrinology & Metabolism

Pros and cons of an aggressive initial treatment with surgery and radioiodine treatment in minimally invasive follicular thyroid carcinoma

Elisa Minaldi, Carlotta Giani, Laura Agate, Eleonora Molinaro, Rossella Elisei

Summary: Surgery is the standard treatment for minimally invasive follicular thyroid cancer (mi-FTC). A case of mi-FTC diagnosed in 1994 was treated with total thyroidectomy and radioiodine ablation. However, the patient had a recurrence with distant metastasis after 24 years.

THYROID RESEARCH (2023)

添加到收藏夹

Article Oncology

A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer

Sophie Leboulleux, Christine Do Cao, Slimane Zerdoud, Marie Attard, Claire Bournaud, Ludovic Lacroix, Danielle Benisvy, David Taieb, Stephane Bardet, Marie Terroir-Cassou-Mounat, Nadege Anizan, Emilie Bouvier-Morel, Livia Lamartina, Georges Lion, Sarah Betrian, Christophe Sajous, Aurelie Schiazza, Marie-Eve Garcia, Renaud Ciappuccini, Martin Schlumberger, Abir Al Ghuzlan, Yan Godbert, Isabelle Borget

Summary: Dabrafenib-trametinib is effective for restoring iodine uptake in BRAF p.V600E-mutated DTC patients, with a 6-month partial response observed in 38% of patients.

CLINICAL CANCER RESEARCH (2023)

添加到收藏夹

Article Endocrinology & Metabolism

MERAIODE: A Phase II Redifferentiation Trial with Trametinib and I-131 in Metastatic Radioactive Iodine Refractory RAS Mutated Differentiated Thyroid Cancer

Sophie Leboulleux, Daniele Benisvy, David Taieb, Marie Attard, Claire Bournaud, Marie Terroir-Cassou-Mounat, Ludovic Lacroix, Nadege Anizan, Aurelie Schiazza, Marie Eve Garcia, Abir Al Ghuzlan, Livia Lamartina, Martin Schlumberger, Yann Godbert, Isabelle Borget

THYROID (2023)

添加到收藏夹

Article Endocrinology & Metabolism

Adrenal insufficiency in thyroid cancer patients treated with tyrosine kinase inhibitors and detected by ACTH stimulation test

L. Valerio, C. Giani, A. Matrone, B. Pontillo-Contillo, E. Minaldi, L. Agate, E. Molinaro, R. Elisei

Summary: More than half of advanced thyroid cancer patients treated with TKI developed subclinical AI, which can occur at various time points and requires regular monitoring and treatment.

JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2023)

添加到收藏夹

Review Endocrinology & Metabolism

Central node dissection in papillary thyroid carcinoma in the era of near-infrared fluorescence

Paulina Kuczma, Marco Stefano Demarchi, Sophie Leboulleux, Christophe Tresallet, Maria Mavromati, Reza Djafarrian, Andrea Mabilia, Frederic Triponez

Summary: The most common site of lymph node metastases in papillary thyroid carcinoma is the central compartment of the neck (level VI). Prophylactic surgical clearance of the level VI in the absence of clinically suspicious lymph nodes (cN0) is still under debate. Arguments against the prophylactic central lymph node dissection (CLND) cite minimal oncologic benefit and concomitant higher operative morbidity. Recently, near-infrared fluorescence imaging has emerged as a potential tool to minimize the risk of hypoparathyroidism associated with CLND.

FRONTIERS IN ENDOCRINOLOGY (2023)

添加到收藏夹

Review Endocrinology & Metabolism

Conservative management of low-risk papillary thyroid carcinoma: a review of the active surveillance experience

Anabella Smulever, Fabian Pitoia

Summary: The detection of low-risk thyroid carcinoma has increased in recent decades, however, disease-specific mortality remained unchanged. Active surveillance has emerged as an alternative approach for these tumors due to the high prevalence of occult carcinomas and the indolent course of this disease. Active surveillance has proven to be a safe and feasible alternative for properly selected patients, with minimal changes in tumor size and low rates of lymph node metastases.

THYROID RESEARCH (2023)

添加到收藏夹

Article Endocrinology & Metabolism

Ultrasound features and risk stratification system in NIFT-P and other follicular-patterned thyroid tumors

Antonio Matrone, Carla Gambale, Erica Pieroni, Luigi De Napoli, Liborio Torregrossa, Gabriele Materazzi, Rossella Elisei

Summary: Objective Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFT-P) is a type of encapsulated follicular variant of papillary thyroid carcinoma (PTC) that has nonaggressive clinical behavior. However, its diagnosis can only be made after surgery, which presents a clinical challenge. This study aims to evaluate the ultrasound features of NIFT-P and compare them with other follicular-patterned thyroid tumors, as well as to test the ability of the main ultrasound risk stratification system (RSS) in identifying NIFT-P.

EUROPEAN JOURNAL OF ENDOCRINOLOGY (2023)

添加到收藏夹

Article Endocrinology & Metabolism

Advances in the management of anaplastic thyroid carcinoma: transforming a life-threatening condition into a potentially treatable disease

Ines Califano, Anabella Smulever, Fernando Jerkovich, Fabian Pitoia

Summary: ATC is a rare thyroid tumor that mainly affects elderly patients. It is characterized by a rapidly growing cervical mass and often presents with metastases at diagnosis. Treatment with a combination of BRAF and MEK inhibitors has improved overall survival in patients with BRAF-mutated ATC. However, effective therapies are still needed for patients with BRAF wild-type ATC, and more high-quality evidence is needed to guide treatment decisions.

REVIEWS IN ENDOCRINE & METABOLIC DISORDERS (2023)

添加到收藏夹

Article Endocrinology & Metabolism

Thirty years of active surveillance for low-risk thyroid cancer, lessons learned and future directions

Anabella Smulever, Fabian Pitoia

Summary: Active Surveillance is a safe and effective non-invasive treatment strategy for low-risk papillary thyroid carcinoma patients. Despite 30 years of experience, there are still limitations to its adoption in certain contexts, including limited understanding of the nature of the disease and a maximalist mindset among certain patients and medical settings.

REVIEWS IN ENDOCRINE & METABOLIC DISORDERS (2023)

添加到收藏夹

Review Endocrinology & Metabolism

Management of radioiodine refractory differentiated thyroid cancer: the Latin American perspective

Fabian Pitoia, Rafael Selbach Scheffel, Ines Califano, Alicia Gauna, Hernan Tala, Fernanda Vaisman, Alejandro Roman Gonzalez, Ana Oliveira Hoff, Ana Luiza Maia

Summary: RAI refractory differentiated thyroid cancer requires a multidisciplinary approach. Availability of multikinase inhibitors and genomic testing differs worldwide, posing challenges in Latin America. Efforts should be made to alleviate the discrepancies and improve accessibility to precision medicine.

REVIEWS IN ENDOCRINE & METABOLIC DISORDERS (2023)

添加到收藏夹

Article Endocrinology & Metabolism

Significance of Thyroglobulin Autoantibodies in Patients With Thyroid Cancer Treated With Lenvatinib

Daniele Sgro, Piercarlo Rossi, Paolo Piaggi, Alessandro Brancatella, Loredana Lorusso, Valeria Bottici, Eleonora Molinaro, Francesco Latrofa, Rossella Elisei, Laura Agate

Summary: This study aimed to evaluate whether serum thyroglobulin autoantibodies (TgAb) could be considered as a surrogate marker for thyroglobulin (Tg) in monitoring the response to lenvatinib treatment in thyroid cancer patients. The results showed that a significant decrease in TgAb levels was associated with favorable response to lenvatinib.

JOURNAL OF THE ENDOCRINE SOCIETY (2023)

添加到收藏夹

Article Endocrinology & Metabolism

The impact of transsphenoidal surgery on pituitary function in patients with non-functioning macroadenomas

Maria Mavromati, Thomas Mavrakanas, Francois R. Jornayvaz, Karl Schaller, Aikaterini Fitsiori, Maria I. Vargas, Johannes A. Lobrinus, Doron Merkler, Kristof Egervari, Jacques Philippe, Sophie Leboulleux, Shahan Momjian

Summary: This study assessed the impact of transsphenoidal surgery on pituitary function in patients with non-functioning pituitary adenomas (NFPAs) and identified predictive factors. The results showed that the recovery rate of pituitary deficiency after surgery was 46% and the rate of new pituitary deficiency was 10%. Male patients and patients with hyperprolactinemia were more likely to experience pituitary function recovery. Rating: 8/10

ENDOCRINE (2023)

添加到收藏夹

Article Oncology

A Misleading Case of NTRK-Rearranged Papillary Thyroid Carcinoma

Marco Maria Germani, Chiara Boccaccio, Antonio Matrone, Eleonora Molinaro, Greta Ali, Mirella Giordano, Rossella Elisei, Gabriella Fontanini, Chiara Cremolini

Summary: This article presents a case of advanced papillary thyroid carcinoma initially misdiagnosed as metastatic lung adenocarcinoma with papillary features. Comprehensive genomic profiling revealed NTRK1-TMP3 fusion and comutation of the TERT promoter. The patient achieved meaningful and durable clinical benefit with tailored treatment targeting NTRK fusion.

ONCOLOGIST (2023)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.